Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 296 clinical trials
Featured trial
  • 690 views
  • 08 Nov, 2020
  • 1 location
Featured trial
ACNS0822: A Randomized, Phase II/III Study of Vorinotat (IND#71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND#7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas

ACNS0822: A Randomized, Phase II/III Study of Vorinotat (IND#71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND#7921) and Local Irradiation Followed by

  • 87 views
  • 08 Nov, 2020
  • 1 location
Featured trial
CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

  • 176 views
  • 08 Nov, 2020
  • 1 location
Featured trial
ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

  • 258 views
  • 08 Nov, 2020
  • 1 location
Featured trial
ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized

  • 112 views
  • 08 Nov, 2020
  • 1 location
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

  • 104 views
  • 13 May, 2022
  • 10 locations
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy nave pediatric patients with progressive Low

neutrophil count
BRAF
glomerular filtration rate
auditory test
vinblastine
  • 2 views
  • 27 Jan, 2022
  • 24 locations
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic

systemic chemotherapy
colorectal adenocarcinoma
bevacizumab
fluorouracil
oxaliplatin
  • 61 views
  • 14 May, 2022
  • 105 locations
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

called BI 905711 combined with chemotherapy and bevacizumab. The purpose of the first part is to find the highest BI 905711 dose participants can tolerate. In the second part, participants with

  • 0 views
  • 09 May, 2022
  • 4 locations
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.

  • 0 views
  • 03 May, 2022
  • 112 locations